Hi Kiska. The advancement of ADC drugs like Enhertu in breast cancers is making it difficult for immutep to progress in this cancer indication. Not much data for adc outside breast cancer. Efti still very much kicking goals in lung and head/neck. Efti might also be combined with adc’s just like we exploring combo with keytruda.Future looking good for immutep.
Media, page-477
-
- There are more pages in this discussion • 267 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
38.0¢ |
Change
0.010(2.70%) |
Mkt cap ! $551.9M | |||
| Open | High | Low | Value | Volume |
| 37.0¢ | 39.0¢ | 37.0¢ | $1.296M | 3.401M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 54900 | 37.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 38.0¢ | 22008 | 1 |
View Market Depth
| Last trade - 16.10pm 28/08/2024 (20 minute delay) ? |
| IMM (ASX) Chart |